Monitoring carbon dioxide (CO2) concentration in a patient is a key aspect of patient monitoring, especially monitoring in intensive care situations and/or during anesthesia. CO2 concentrations provide information about patient acidity, which is an important descriptor of the balance between ventilation and patient metabolism. Directly determining patient arterial blood CO2 partial pressure (PaCO2) requires drawing a blood sample from the patient and conducting offline laboratory analysis. Such blood sampling only provides delayed information about arterial blood CO2 concentrations, and such information is only available intermittently. For example, even for ICU patients at risk for high arterial blood CO2 concentrations, blood samples are typically only taken once or twice daily. Furthermore, arterial sampling and the blood analysis are labor-intensive and provide opportunities for human error and sample handling.
Thus, current medical monitoring technology measures CO2 concentrations in breathing gas expired by the patient (EtCO2) to gauge arterial CO2 concentrations. The international standard set for anesthesia delivery and monitoring systems mandates the use of expired CO2 (EtCO2) monitoring when a patient is undergoing anesthesia. The rationale is that during anesthesia the EtCO2 is a surrogate for, or estimate of, patient arterial blood CO2 partial pressure (PaCO2). However, the relationship between EtCO2 and PaCO2 is not always direct or as expected, especially in situations involving patients with pulmonary impairments or conditions.
The present inventor has recognized that, since the relationship between EtCO2 and PaCO2 is not always direct or as expected, EtCO2 is not an ideal proximate for PaCO2 and that a better measurement of PaCO2 is needed. In certain situations, such as in patients with a pulmonary shunt or a pulmonary emboli, the EtCO2 can be much lower than the PaCO2, even reaching one-third or less of the PaCO2 value. Further, the inventor recognized that direct determination of PaCO2 through blood sampling and lab analysis is inefficient and cannot provide the real-time data needed in manning anesthesia and intensive care environments. Accordingly, the present inventor developed the method and system described herein which reduces the difference between EtCO2 and PaCO2 and provides improved real-time estimation of arterial CO2 partial pressure.
A method of estimating the partial pressure of carbon dioxide in arterial blood of a patient comprises determining an arterial oxygen saturation for a patient, determining a breathing gas carbon dioxide value, and determining breathing gas oxygen value. The method further includes calculating an arterial blood carbon dioxide partial pressure for the patient based on at least the arterial oxygen saturation value, the breathing gas carbon dioxide value, and the breathing gas oxygen value for the patient.
One embodiment of the patient monitoring system comprises a device for noninvasively measuring an arterial hemoglobin oxygen saturation value of a patient, a breathing gas analyzer, and a calculation unit. The breathing gas analyzer is configured to measure a peak carbon dioxide partial pressure in the breathing gas expired by the patient and to measure a breathing gas oxygen value. The calculation unit is configured to calculate an arterial oxygen saturation value for the patient based on the arterial hemoglobin oxygen saturation value and to calculate an arterial blood carbon dioxide indicator value of the patient based on at least the arterial oxygen saturation value and the breathing gas oxygen value for the patient.
An embodiment of the method for monitoring a patient includes estimating an amount of carbon dioxide in arterial blood of a patient by noninvasively measuring an arterial oxygen saturation value for the patient, determining a breathing gas oxygen value, measuring a peak carbon dioxide partial pressure of a breathing gas expired by the patient and calculating an arterial blood carbon dioxide partial pressure of the patient based on at least the arterial oxygen saturation value, the breathing gas carbon dioxide value, and the breathing oxygen value for the patient. The method further includes comparing the arterial blood carbon dioxide partial pressure to a peak carbon dioxide partial pressure expired by the patient and generating an alert if the arterial blood carbon dioxide partial pressure differs from the peak carbon dioxide partial pressure expired by the patient by more than a predetermined amount.
Various other features, objects and advantages of the invention will be made apparent from the following description taken together with the drawings.
The drawings illustrate the best mode presently contemplated of carrying out the disclosure. In the drawings:
The process of ventilation, circulation, and metabolism consumes oxygen (O2) and produces carbon dioxide (CO2). Thus, there is a declining concentration gradient of O2 from ambient air to venous blood and an increasing gradient for CO2.
The O2 and CO2 levels are depicted for six different ventilation compartments, or stages, including insufflation gas partial pressure (Pi) 6-7, exsufflation end-tidal gas pressures (Pet) 8-9, alveolar gas partial pressure (PA) 10-11, end-capillary partial pressure (Pcap) 12-13, arterial gas partial pressure (Pa) 14-15, and venous gas partial pressures (Pv) 16-17. Tissue metabolism consumes oxygen (O2) and produces carbon dioxide (CO2). Blood circulation carries the O2 to tissue and the CO2 out from the tissue. This circulation passes through lung, which comprises a large-area thin membrane between the blood and alveolar air. Gas content of the blood leaving the lung represents arterial blood while the arriving gas represents venous blood. The membrane allows gas diffusion between the capillary blood and alveolar air. Alveoli is the lung gas compartment where the breathing gas communicates with blood flow in pulmonary capillaries through a diffusion membrane allowing gas pressure equilibration between the gas and blood. Because of metabolism consuming O2 and producing CO2, the blood arriving to lungs has low O2 and high CO2 concentrations compared to the alveolar gas. Thus, in the lung the CO2 diffuses from blood to the alveoli and O2 from alveoli to blood to equilibrate the gas pressure differences. Cyclic insufflation and exsufflation (ventilation) changes the alveolar gas with ambient gas providing fresh O2 to alveoli and clearing accumulating CO2 out. Thus, the end-capillary partial pressure (Pcap) 12-13 is the capillary point where the blood is leaving the alveolar gas exchange region
As can be seen from
As is shown in
The relationship between hemoglobin oxygen saturation and PaO2 is presented in
Returning to
At step 28, PaCO2 is calculated based on the PaO2, PetCO2, and breathing gas O2 concentration values. Once the PaCO2 value is calculated or estimated at step 28, it may be compared to the PetCO2 value at step 30. If the difference between the PaCO2 value and the PetCO2 value is greater than a predetermined amount, step 32, then the patient may be experiencing high arterial CO2 values and the clinician may need to be alerted. On the other hand, if the difference appears only in a single measurement, it could be due to measurement error or artifact. Thus, step 34 assesses whether the difference between the PaCO2 and PetCO2 values have been sustained for at least a predetermined amount of time. If not, then the method begins again at step 20 by measuring the hemoglobin oxygen saturation to determine whether the discrepancy between the PaCO2 and the PetCO2 is an error or not. If the difference between the PaCO2 value and the PetCO2 value has been sustained for at least a predetermined period of time, then an alert may be generated at step 36 to notify the clinician of the discrepancy between the two CO2 values. The clinician may then take steps to verify whether the arterial CO2 values are high and/or may adjust the patient care in order to address the high CO2 levels. In still other embodiments, PaCO2 calculation may be part of an automatic ventilation and/or anesthesia control algorithm. For example, an automatic ventilation control algorithm may seek to maintain a user-set, or user-defined, target PaCO2 level.
For example, if the PaCO2 value exceeds the PetCO2 value by more than 2 kPa, the method may generate an alert to alert the clinician of the discrepancy. Alternatively or additionally, this method may require that the difference of at least 2 kPa be sustained for at least a predetermined period of time, such as for a set number of breath cycles or a set number of seconds, etc. In other embodiments, an alert may be generated every time the difference between PaCO2 and PetCO2 exceeds a predetermined value. Alternatively or additionally, the time requirement for the difference between PaCO2 and PetCO2 could be variable depending on the magnitude or value of the difference.
PaCO2 values may be determined, such as at step 28 of
PaCO2=PetCO2+k·(PxO2−PaO2)
wherein x designates an oxygen pressure measured from the breathing gas (e.g., either PiO2 or PetO2) and k is a proportionality factor. The proportionality factor k is determined empirically using clinical measurements. More specifically, the empirical determination may include collecting information of patient breathing gases and arterial oxygen saturation at the time of taking blood sample to determine true PaCO2 value. This empirical determination may also entail this collection with a large number of patients representing normal and deformed pulmonary function and covering the range of true PaCO2 values. The difference between the true PaCO2 and estimated PaCO2 is calculated and this calculation includes the factor k. Identifying the optimum value for the k-factor may further comprise, as an example, calculating the difference for all experimental measurements, calculating the sum of the squares of these differences, and selecting k-factor that minimize this difference. For example, if PxO2 is PetO2, the proportionality factor may be between 0.05 and 0.06. If PxO2 is equal to PiO2, then the proportionality factor may be between 0.04 and 0.05. The smaller factor for PiO2 reflects the higher value of PiO2 compared to PetO2. The optimum k-factor may also be determined separately for ranges of measured values. As an example, conditions where measured breathing gas oxygen value is large or small may have different k-factors. Similarly, arterial hemoglobin oxygen saturation value low and high can have different k-factors.
The relationship between arterial and breathing gas partial pressure for oxygen and for carbon dioxide is however not constant as the equation indicates but may vary depending on level and type of lung disorders. The arterial carbon dioxide estimation accuracy can be improved by compensating with an additional difference term determined at the time of blood sampling. This term determines the difference between the true and estimated carbon dioxide partial pressures. Adding this difference to the right side of the equation calibrates the estimation to the particular lung disorder.
In another embodiment, an arterial blood carbon dioxide indicator value can be calculated in place of or in addition to the PaCO2 value. For example, such an arterial blood carbon dioxide indicator value may be the oxygen pressure difference between the breathing gas oxygen value and the arterial oxygen saturation value (PxO2−PaO2). This value, which may or may not be multiplied by a proportionality factor k may be used to make a determination about or estimation of whether or not the CO2 level in the patient's arterial blood is high. In other words, if such an arterial blood carbon dioxide indicator value, such as PxO2−PaO2, is greater than a predetermined amount, then it may be known that PaCO2 is exceeding PetCO2 by more than is desired or tolerable. Thus, such an arterial blood carbon dioxide indicator value may provide a short hand, or surrogate, for the full determination of the PaCO2 value, and information can be gleaned about the patient's arterial CO2 values without actually calculating the PaCO2 and comparing it to the PetCO2 value. For example, if the oxygen pressure difference (PxO2−PaO2) is high, then it may be determined that the CO2 pressure difference (PaCO2−PetCO2) is also high without actually calculating that difference.
As explained above, the oxygen dissociation curve depends on body pH. Thus, the use of the oxygen-hemoglobin dissociation curve has the potential to introduce some error into the calculation. Specifically, between a normal and an acidic patient, the PaO2 difference is 4.3 kPa, and the error resulting from this is 0.24 kPa (0.055×4.3). Such error is usually tolerable for most monitoring purposes and is much less than the potential difference between the PetCO2 and PaCO2 values, which may be as high as 5-7 kPa.
The exemplary system 2 further comprises a calculation unit 61 to calculate a value indicating carbon dioxide concentrations in arterial blood, such as the arterial blood carbon dioxide partial pressure value an/or the arterial blood carbon dioxide indicator value described above. Furthermore, the exemplary patient monitoring system 2 may comprise a user interface 63. The user interface 63 may be configured to display values to a clinician, such as PaCO2, PetCO2, and/or arterial blood carbon dioxide indicator values. The user interface 63 may also be configured to generate an alert to alert a clinician that carbon dioxide concentrations in a patient are too high, such as if PaCO2 exceeds PetCO2 by more than a predetermined amount, or an arterial blood carbon dioxide indicator value exceeds a predetermined value.
This written description uses examples to disclose the invention, including the best mode, and also to enable any person skilled in the art to make and use the invention. The patentable scope of the invention is defined by the claims, and may include other examples that occur to those skilled in the art. Such other examples are intended to be within the scope of the claims if they have structural elements that do not differ from the literal language of the claims, or if they include equivalent structural elements with insubstantial differences from the literal languages of the claims.